Genetic study of liver injury from a leukemia medicine
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be newly diagnosed with acute lymphoblastic leukemia (ALL) and have not had prior ALL treatment
- Be receiving asparaginase as part of your first ALL treatment
- Be able to understand the study and willing to sign consent
- If joining from past treatment records: you received asparaginase between 2012 and 2017 and are currently a USC patient
- Not qualify if you are unable to provide informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether levocarnitine can reduce liver injury from a chemotherapy medicine called asparaginase in people with high-risk acute lymphoblastic leukemia (ALL). If you’re eligible, you would take levocarnitine by mouth alongside your planned standard cancer treatment to see if the liver stays healthier.
This study gathers key health information at the start of treatment for children and teens newly diagnosed with certain types of leukemia or lymphoma. The goal is to find the best way to begin therapy right away, without waiting for extra tests.
This study looks at leukemia “genetic clues” using special stored samples, including cord blood saved at birth. It may help researchers better understand leukemia biology and how common mutations may show up early.
This study uses whole genome sequencing to analyze your leukemia's DNA. The goal is to find unique genetic changes that may help guide future treatments, though this study does not recommend any specific therapy.
This study looks at the gut microbiome (tiny organisms in the gut) and metabolome (small chemicals in the body) in children and teens with newly diagnosed ALL. It may help researchers understand what is happening in the body early in treatment and could guide future, more personalized care.
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.